Friday, 27 Mar 2020

You are here

Mortality in Gout Increased

Two current articles in the Journal of Rheumatology address issues surrounding mortality risk among those with new and established gout.

Vincent et al assessed predictors of mortality in patients with a recent onset of gout (disease duration < 10 years). They analyzed 295 patients with a mean followup duration of 5.1 years, during which time there were 43 deaths (14.6%).

Factors independently associated with an increased mortality risk included: older age (HR > 9.3 for those over 80 yrs.); Māori or Pacific ethnicity (HR 2.48); loop diuretic use (HR 3.99); elevated serum creatinine and the tophi (HR 2.85).  Amongst these only subcutaneous tophi was the only baseline variable independently associated with both CV death and all cause death.

A gout disease duration < 10 years has an increased risk of death. Subcutaneous tophi at baseline is an independent predictor of mortality, from both CV and non-CV causes.

Kang and Korean investigators also analyzed mortality risk in terms of gender and serum urate (SUA) levels. (Citation source: http://buff.ly/2omFieW

During 12.3 years of followup there was 27,490 deaths, amounting to 6.9% of men and 3.1% of women died.

The bimodal (U shaped) association between SUA levels in men and mortality was not seen in women. Thus a significant interaction of gender was seen with the SUA-mortality association.

Thus a higher mortality rate was seen with very low SUA levels (SUA ≤ 4.0 mg/dl, adjusted HR 1.413) and higher SUA levels in men (> 8.0 mg/dl, adjusted HR 1.140). Women failed to show any significant association between SUA and mortality.

Novel to this study was the observation that lower SUA (after correction) was an independent risk factor for all-cause mortality in men with normal kidney function.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Interleukin-37 Targeting in Gout

The Annals of Rheumatic Disease reports that interleukin- 27 (IL-37) may play an important role in the pathogenesis of gout, paving the way for future therapy with recombinant IL-37 in gouty arthritis.

Activation of the inflammasome by monosodium urate crystals is thought to be paramount to the innate immune response that drives IL-1-mediated joint inflammation in gout.

Hyperuricemia Predisposes to Coronary Artery Disease in Men

There are numerous associations between hyperuricemia and cardiovascular disease (CVD). An analysis of the Swedish SCAPIS Pilot study shows that higher levels of serum urate (SU) are associated with an increase in coronary artery calcification score in men but not in women. SU is not associated with common carotid intima-media thickness and carotid plaque scores in either men or women.

Hypersensitivity Reactions and Gout Tx: Watch the Dose

Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.